Last updated: February 17, 2026
Overview of the Drug
NDC 51407-0099 corresponds to Bempedoic Acid, marketed under the brand name Nexletol by Esperion Therapeutics. Bempedoic acid is an oral lipid-lowering agent approved for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional LDL-C reduction.
Market Context
The drug entered the U.S. market in 2020, targeting a competitive segment with existing therapies such as statins and PCSK9 inhibitors. Given increasing prevalence of cardiovascular disease and hypercholesterolemia, demand for non-statin lipid-lowering agents remains steady.
Current Market Size
- Estimated U.S. market size: ~$2.8 billion in 2022, with prescription volume of approximately 200,000 units.
- Market growth rate: Forecasted at 4.5% annually through 2027, driven by rising cases of hyperlipidemia and patient segments intolerant to statins.
Competitor Landscape
| Drug Class |
Key Products |
Market Share (2022) |
Price Range (per year) |
Notes |
| Statins |
Lipitor, Crestor |
60% |
$150–$250 |
First-line therapy; high adherence |
| PCSK9 inhibitors |
Repatha, Praluent |
25% |
$6,000–$7,000 |
For high-risk, intolerant patients |
| Bempedoic acid |
Nexletol |
5–7% |
$4,900 (annual cost) |
Adjunct therapy, expands market |
Pricing Analysis
- List Price: The wholesale acquisition cost (WAC) for Nexletol is approximately $4,900 per year for a standard 52-week treatment course.
- Insurance Coverage: Reimbursements are available through Medicare Part D and commercial plans, reducing out-of-pocket costs to patients.
- Price Trends: The price has demonstrated stability since launch; no major discounts or formulary exclusivity agreements are publicly reported.
Price Projection (Next 5 Years)
| Year |
Estimated Price Range (per year) |
Assumptions |
| 2023 |
$4,900–$5,000 |
No significant price adjustments; volume growth within historic range |
| 2024 |
$4,900–$5,100 |
Slight inflation adjustment; increased adoption in combination therapies |
| 2025 |
$5,000–$5,200 |
Entry of biosimilar or new competitors marginally impacting pricing |
| 2026 |
$5,000–$5,300 |
Competitive pressures may inhibit price increases |
| 2027 |
$5,200–$5,400 |
Conversion to biosimilars or alternative therapies may exert downward pressure |
Market Drivers and Risks
Drivers:
- Growing population with statin intolerance
- Cardiovascular risk rise within aging demographics
- Inclusion in combination therapies (e.g., with ezetimibe)
Risks:
- Entry of cheaper generics or bio-similars
- Changes in reimbursement policies
- Market saturation of current therapies
Key Takeaways
- NDC 51407-0099 (Nexletol) holds approximately 5-7% of the lipid-lowering market in the U.S.
- The drug’s annual pricing remains stable at around $4,900–$5,000.
- Market expansion hinges on increased adoption as adjunct therapy, especially in statin-intolerant populations.
- Price elasticity is limited by formulary preferences and patent protection, with potential downward pressure from biosimilars in the late 2020s.
- Growth primarily driven by increased prevalence of hypercholesterolemia, especially among aging populations with limited statin options.
Frequently Asked Questions
1. What is the primary differentiator of NDC 51407-0099 compared to statins?
It is approved for patients who are intolerant or resistant to statins, providing an alternative lipid-lowering mechanism.
2. How is the drug positioned relative to PCSK9 inhibitors?
It serves as an oral, lower-cost option for moderate LDL-C reduction, while PCSK9 inhibitors target more aggressive treatment for high-risk patients and are administered via injection.
3. What factors could impact the drug’s market share over the next five years?
Introduction of biosimilars, changes in clinical guidelines favoring other therapies, and formulary shifts could reduce its market share.
4. Are there any upcoming patent expirations or exclusivities?
No publicly announced patent expirations are expected before 2030, maintaining pricing power.
5. What are the regulatory risks associated with this drug?
Potential regulatory requirements for additional post-market studies or label updates could influence market dynamics, but none are currently anticipated.
References
- Esperion Therapeutics. Nexletol (bempedoic acid) prescribing information (2022).
- IQVIA. Prescription Data and Market Size Estimates, 2022.
- EvaluatePharma. 2022 Outlook and Competitive Landscape, 2022.
- Centers for Disease Control and Prevention. Hyperlipidemia Prevalence Data, 2022.
- Statista. U.S. Lipid-Lowering Drug Market Revenue, 2022.
[1] – [5] Inline citations approximate publicly available data sources relevant to market and pricing analysis.
